Pilot program demonstrates measureable benefits for people with schizophrenia

 

Evidence-based tools help improve daily functioning and increase treatment transparency and accountability

 

Washington, D.C., USA (March 6, 2012) – People with schizophrenia report improved functioning after participating in a new, evidence-based clinical program, according to results announced today from a six-month pilot. The program, Advancing Standards of Care for People with Schizophrenia, was spearheaded by the National Council for Community Behavioral Healthcare (National Council) and administered at 10 community behavioral health organizations across the country. The program significantly improved communication, social interaction and coping skills for persons recovering from schizophrenia.

 

"Although society’s understanding of schizophrenia has progressed over the decades, we can do more to help people with the illness recover," said Linda Rosenberg, President and CEO of the National Council. "This program promotes practitioner and consumer partnerships. Together they measure progress and reinforce what works. It’s a true step forward for people with schizophrenia and the organizations that serve them."

 

The program revolved around two evidence-based tools: a group curriculum to help adults better understand and self-manage their mental health condition; and a functional assessment tool, which tracks a person’s ability to independently carry out everyday tasks. The tools encourage participants to take control of their mental illness, discuss it with others, and monitor progress. Participants said they found this helpful in addressing the misconceptions others may have about them.

 

According to one 49-year-old treated at Hill Country Mental Health in Kerrville, Texas, participating in the program gave her confidence to face her diagnosis and fears."I was frightened, isolated and sometimes in denial about my illness," she said. "After participating in this program, I’m much more confident discussing things openly with my mental health provider and even sharing what I’ve learned with people around me."

 

Health care providers that participated in the program said that the measurement tool gave them accurate and reliable data that supported increased transparency and accountability.

 

"We are all adapting to health care system changes that recognize the value of care over volume of care," said Linda Werlein, CEO of Hill Country Mental Health. "This program provided both an effective curriculum, and a way to demonstrate progress."

 

Rosenberg also notes that the program’s success holds great potential for replication. She emphasizes, "the participating behavioral health centers found the interventions to be effective, easy to administer and results-oriented, and many of them plan to spread the program throughout their organizations."

 

Christopher, a client at AltaPointe Health Systems in Mobile, Alabama, says the program encouraged him to think about and solve problems in new ways. "I learned valuable life skills, how to stay healthy, manage my anger, and prevent a relapse," he explained.

 

 

Key Results

 

  • The 10 pilot sites started with a total of 5,687 clients in December, 2010.
      • The average age of participants was 45.7 years, many of whom had already been in treatment for years
      • 20 percent of participants scored an "inability to function in all areas" on the pre-interventional functional assessment
      • 50 percent of participants scored "major impairment" in at least five critical areas of functioning in daily activities
  • The average cumulative functional score from all participants rose from an initial 37.76 to 41.07 over the course of six months.
  • Overall, there was a statistically significant gain in three sub-scales: communications, interaction with one’s social network, and coping skills.
  • There was an overall attrition rate of 48 percent, consistent with community based treatment protocols.

 

 

A full list of pilot sites in the Advancing Standards of Care for People with Schizophrenia program and a copy of the outcomes report program can be found at www.thenationalcouncil.org

 

Funding for the Advancing Standards of Care for People with Schizophrenia program was made possible through a grant from Sunovion Pharmaceuticals Inc.

 

 

About Schizophrenia

 

Schizophrenia is a brain disorder that can impair a person’s ability to think clearly and relate to others. People with schizophrenia may become withdrawn or have difficulty in everyday situations. Schizophrenia typically develops in adolescence or early adulthood, although it may occur later in life. Schizophrenia varies in severity, can be treated and recovery is possible.

 

 

About the National Council

 

The National Council is a not-for-profit, 501(c) (3) association of 1,950 community healthcare organizations that provide treatment and rehabilitation for mental illnesses and addiction disorders to nearly 6 million adults, children and families in communities across the country. Learn more at www.thenationalcouncili.org

 

About Sunovion

 

Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the central nervous system (CNS) and respiratory disease areas and improve the lives of patients and their families. Sunovion is an indirect, wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd. More information is available at www.sunovion.com

 


 

Chandler Chicco Agency, 06.03.2012 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…